source
- Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejectionAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…
- Lilly uses indirect data to argue its oral GLP-1 pill may outperform Novo’s semaglutideEli Lilly’s weight‑loss drug Foundayo has seen a slower launch than expected, according to BMO Capital Markets, which noted the product is lagging behind competitors. To bolster its market case, L…